Management of Prostate Cancer: Global Strategies

Slides:



Advertisements
Similar presentations
Pascal Rischmann  European Urology Supplements 
Advertisements

Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Volume 51, Issue 2, Pages (February 2007)
Volume 27, Issue 4, Pages (December 2016)
Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management  Michael O’Leary  European Urology Supplements 
Fred Saad  European Urology Supplements 
Renal Cell Carcinoma: Prognostic Factors and Patient Selection
Prostate Cancer: Highlights from 2006
Claude C. Schulman, Jacques Irani, Juan Morote, Jack A
Control of Prostate Cancer by Transrectal HIFU in 227 Patients
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Volume 72, Issue 5, Pages (November 2017)
Treatment of Advanced and Metastatic Renal Cancer: A Revolution?
What is New in Hormone Therapy for Prostate Cancer in 2007?
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance  Adam B. Weiner, Ruth Etzioni, Scott E. Eggener 
Volume 54, Issue 5, Pages (November 2008)
Volume 67, Issue 6, Pages (June 2015)
Volume 71, Issue 5, Pages (May 2017)
Localised and Locally Advanced Prostate Cancer: Who to Treat and How?
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Luis Martínez-Piñeiro  European Urology Supplements 
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Volume 58, Issue 1, Pages 1-7 (July 2010)
Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection
RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer  Matthew R. Smith  European Urology Supplements 
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial
Volume 50, Issue 5, Pages (November 2006)
Optimising Hormone Therapy in Advanced Disease
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Yong-jiang Hei  European Urology Supplements 
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Jacques Irani  European Urology Supplements 
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Volume 53, Issue 1, Pages (January 2008)
Neal Shore  European Urology Supplements 
The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Long-Term Hormonal Therapy: Who Would Benefit?
Bladder Cancer: Highlights from 2006
The Hallmarks of BPH Progression and Risk Factors
Challenges and Opportunities in Hormone-Resistant Prostate Cancer
Christian Stief  European Urology Supplements 
Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma  Fred Saad  European Urology.
New Trends in Managing the Prostate Cancer Patient
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Axel Heidenreich  European Urology Supplements 
Improving Flexibility and Quality of Life for Your Patients: A Must?
Profile of Silodosin European Urology Supplements
Highlighting Unmet Needs: Real Patients, Difficult Choices
The Increasing Responsibility of the Urologist in Maintaining Bone Health in Prostate Cancer Patients  Kurt Miller  European Urology Supplements  Volume.
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Volume 53, Issue 6, Pages (June 2008)
Beyond Skeletal-Related Events
Fernando P. Secin, Fernando J. Bianco, Nicholas T
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma  Jan Roigas  European Urology Supplements  Volume.
Volume 51, Issue 2, Pages (February 2007)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer  Noel W. Clarke  European Urology Supplements 
Axel Heidenreich  European Urology Supplements 
Presentation transcript:

Management of Prostate Cancer: Global Strategies Antonio Alcaraz  European Urology Supplements  Volume 5, Issue 18, Pages 890-899 (November 2006) DOI: 10.1016/j.eursup.2006.08.005 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 Prognostic value of PSA velocity (PSAV) in detecting clinically significant pCA in an early detection setting [13]. Less-aggressive pCA was defined as stage <T2b, Gleason score <7; more-aggresive pCA was defined as stage ≥T2b, Gleason score ≥7. European Urology Supplements 2006 5, 890-899DOI: (10.1016/j.eursup.2006.08.005) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 2 Comparison of percentage of positive surgical margins (PSM), nerve-sparing procedures, and pCA stages in patients treated with RP between 1993 and 2004 (ESPRE study). n=10,553 [24]. European Urology Supplements 2006 5, 890-899DOI: (10.1016/j.eursup.2006.08.005) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 3 Five- and 10-yr survival outcomes after RP in patients with cT3a pCA (n=200) [28]. BPFS: biochemical progression-free survival; CPFS: clinical progression-free survival; CSS: cancer-specific survival; OS: overall survival. Mean follow-up=70.6 mo. European Urology Supplements 2006 5, 890-899DOI: (10.1016/j.eursup.2006.08.005) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 4 Comparison of external beam radiotherapy (EBRT) and RP in terms of survival and disease progression after median follow-up of 67 mo [29]. European Urology Supplements 2006 5, 890-899DOI: (10.1016/j.eursup.2006.08.005) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 5 Long-term risk for first and second skeletal-related events (SREs) in patients with metastatic pCA treated with zoledronic acid (ZA) compared with placebo [61]. European Urology Supplements 2006 5, 890-899DOI: (10.1016/j.eursup.2006.08.005) Copyright © 2006 European Association of Urology Terms and Conditions